Search

everythinglearnresearchcommunity

for

Search:↓

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

The patient's hair loss from alopecia totalis returned despite initial successful treatment.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

Co-trimoxazole successfully treated a girl with multiple autoimmune symptoms.

Relapsing polychondritis might be linked to alopecia areata due to immune system factors.

Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.

COVID-19 can trigger a relapsing form of hair loss, requiring long-term treatment strategies.

Allergen desensitization reduces hair loss severity in dust-mite allergic alopecia areata patients.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.

Longer 3 mm needles were most effective for dog hair regrowth, but hair loss often returned and some dogs felt itchy.

Diphenylcyclopropenone treatment helps prevent hair loss relapse in alopecia areata patients.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

PUVA treatment led to significant hair regrowth in over half of the patients with alopecia areata totalis and universalis.

Diphencyprone (DPC) is an effective and safe long-term treatment for alopecia areata, especially with maintenance therapy.

Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.

Systemic corticosteroids don't prevent severe alopecia areata from spreading or relapsing.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.

High-dose corticosteroids and methotrexate had a modest effect on severe childhood alopecia, but side effects and relapse were concerns.

People who get alopecia areata after age 50 usually have mild symptoms, high chances of hair regrowth, and often have other health conditions.

Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.

Alopecia areata in children is usually mild and effectively treated with strong topical steroids.

Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.